TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02467387
Drug: Lactated Ringer's Solution
Normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One time infusion 1.5mL/kg
Study: NCT04355156
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated
Study: NCT00434863
Drug: botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00143221
Drug: Viagra
Normalized name: Viagra
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03591146
Drug: Naropin
Normalized name: Naropin
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
Study: NCT01029002
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
Study: NCT00052299
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00052299
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00052299
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00052299
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00052299
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02683525
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
Study: NCT02204241
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02204241
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004137
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01251172
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03213626
Drug: Cabozantinib 40 MG
Normalized name: cabozantinib 40 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To be taken orally once daily
Study: NCT03213626
Drug: Erlotinib 100Mg Tab
Normalized name: ERLOTINIB 100MG TAB
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be taken orally once daily
Study: NCT03445858
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
Study: NCT03445858
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
Study: NCT02362308
Drug: mineralocorticoid receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
Study: NCT00004137
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004137
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00142519
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
Study: NCT00142519
Drug: methadone and morphine
Normalized name: morphine and antispasmodics
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
Study: NCT03072121
Drug: Shexiang Baoxin pill
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional western medicine \& shexiang baoxin pill
Study: NCT03072121
Drug: Aspirin Enteric-coated Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg tablet, one tablet daily.
Study: NCT03072121
Drug: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Normalized name: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one tablet daily. (for patients who can't use aspirin)
Study: NCT03072121
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet, two tablets each night.
Study: NCT03072121
Drug: Isosorbide Mononitrate Tab 20 MG
Normalized name: isosorbide mononitrate 20 MG
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet two times daily.
Study: NCT03072121
Drug: Metoprolol Tartrate Tab 25 MG
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg or 25 mg two times daily.
Study: NCT03072121
Drug: Trimetazidine Dihydrochloride Tablets
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet, one tablet three times daily.
Study: NCT04158713
Drug: Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
Study: NCT02162485
Drug: Salmeterol/fluticasone Easyhaler
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02162485
Drug: Salmeterol/fluticasone Easyhaler with charcoal
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02162485
Drug: Seretide Diskus
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01468909
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01468909
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00169988
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00169988
Drug: sertraline-primary
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00849264
Drug: chemotherapy with endostar
Normalized name: Primatene with ephedrine Pill
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/d×14d
Study: NCT00849264
Drug: treatment with CBP and 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CBP 300mg/d×2d，5-FU 1000mg/d×5d
Study: NCT01996306
Drug: 5-FU Bolus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
Study: NCT01996306
Drug: 5-FU Infusion
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
Study: NCT03443843
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Normalized name: loratadine / pseudoephedrine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
Study: NCT03443843
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
Study: NCT02808312
Drug: Cilofexor
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally in a fed state on Day 1
Study: NCT03927248
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: See description in Arms/Groups section
Study: NCT02324842
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
Study: NCT02324842
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Study: NCT00115349
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
Study: NCT00115349
Drug: Deferiprone (L1)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
Study: NCT02805556
Drug: BMS-663068
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single oral dose of BMS-663068
Study: NCT02805556
Drug: BMS-626529
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single intravenous dose of \[13C\]BMS 626529
Study: NCT00285298
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03374514
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: instilation of the solution in the middle ear
Study: NCT02600325
Drug: Grazoprevir/Elbasvir 100mg/50mg
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grazoprevir/Elbasvir 100mg/50mg
Study: NCT03446534
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imacillin mixture
Study: NCT01480141
Drug: BIBW 2992 (Afatinib)
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
Study: NCT01345578
Drug: human hepatocyte transplantation
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation.
Study: NCT02315287
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of two different thiazolidinediones
Study: NCT02315287
Drug: Lobeglitazone
Normalized name: lobeglitazone
DrugBank: Lobeglitazone (DB09198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of two different thiazolidinediones
Study: NCT00216099
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
Study: NCT02180503
Drug: BI 1356 BS PIB - high dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02180503
Drug: BI 1356 BS tablet - high dose
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02180503
Drug: BI 1356 BS tablet - high dose with food
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00798694
Drug: Xalatan
Normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Study: NCT00798694
Drug: Travatan Z
Normalized name: Travatan Z
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
Study: NCT03346369
Drug: Lanthanum Carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
Study: NCT00258089
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00734773
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
Study: NCT00734773
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~* For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~* During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter.
Study: NCT00734773
Drug: Procarbazine hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
Study: NCT00734773
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
Study: NCT02991157
Drug: Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01643759
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
Study: NCT00611897
Drug: placebo and ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo N-acetylcysteine
Study: NCT00966940
Drug: Travoprost 0.004% ophthalmic solution (TRAVATAN)
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Study: NCT00966940
Drug: Tafluprost 0.0015% ophthalmic solution
Normalized name: Tafluprost 0.0015% Ophthalmic Solution
DrugBank: Tafluprost (DB08819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
Study: NCT01842308
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01842308
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00439673
Drug: 5-Azacytidine
Normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00439673
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00439673
Drug: ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03219593
Drug: Apatinib mesylate tablets
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
Study: NCT00009815
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00009815
Drug: tegafur-uracil
Normalized name: Tegafur-uracil
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00308438
Drug: Teduglutide (ALX-0600)
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.1 mg/kg injected subcutaneously daily
Study: NCT00114283
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02316756
Drug: PF-06648671
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Pfizer compound which will be dosed as oral suspension
Study: NCT03811678
Drug: Kangdaprevir Sodium Tablet
Normalized name: sodium fluoride Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet，administered orally once daily
Study: NCT02934412
Drug: SHR-1314
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
Study: NCT04584112
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab 840 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of every 28-day cycle.
Study: NCT04584112
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1680 mg administered by IV infusion on Day 1 of every 28-day cycle.
Study: NCT00752609
Drug: Peginesatide
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
Study: NCT01542476
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study: NCT03631862
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
Study: NCT01657448
Drug: Methenamine and Methylthioninium chloride
Normalized name: methylthioninium chloride
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
Study: NCT01657448
Drug: Phenazopyridine
Normalized name: Phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
Study: NCT03029650
Drug: Intravenous scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg via intravenous injection